5 Key Takeaways
-
1
An integrated development approach is essential for a successful CMC section in new drug applications.
-
2
Balanced pragmatism and risk-based decisions are crucial during early-phase drug substance development.
-
3
The General information section establishes a scientific baseline for drug substance characterization.
-
4
Control specifications in early development should remain pragmatic, allowing flexibility in acceptance criteria.
-
5
Reference standards and packaging must comply with regulations and support stability testing in early phases.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
